The rapid test is included on the World Health Organization (WHO) worldwide Emergency Use Listing. Credit: Mufid Majnun on Unsplash.

Premier Medical will submit an application seeking Emergency Use Authorization (EUA) for its Sure Status COVID-19 Antigen Card Test from the US Food and Drug Administration (FDA) for distribution and use in the country.

The rapid chromatographic immunoassay is for the qualitative detection of antigens specific to SARS-CoV-2 in human nasopharynx.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The World Health Organization (WHO) has included the rapid test in its worldwide Emergency Use Listing.

Premier Medical noted that it is the third company in the world and the only Indian-based company to achieve the listing.

Performed by taking a sample from the nose, the simple and affordable test can aid in detecting viral genetic material within the sample

The test is based on colloidal gold immunochromatography and offers results in roughly 15 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With 100% specificity and 94.5% sensitivity, the assay can aid in testing people rapidly and conveniently in various settings, including schools, offices and doctor’s clinics, without requiring any extra equipment.

The test is developed and manufactured completely in India and will be distributed from Somerset, New Jersey, US, by Premier Medical USA.

The company is also developing a test for the detection of other Covid-19 variants based on its patented platform technology and rapid saliva testing, which would help to bring the virus and its transmission under control.

Premier Medical is focused on developing, manufacturing and distributing diagnostic testing for infectious diseases, such as human immunodeficiency virus (HIV), Malaria, Hepatitis and Syphilis.

Furthermore, it has partnered with the Centers for Disease Control and universities to develop novel tests for different infectious diseases.